

ACL Laboratories COVID-19 and Influenza Activity Report


Updated: Nov 14, 2021



RESPIRATORY PATHOGEN PANEL Nov 14, 2021 Positivity Rate (%)



MONTH	FLU A Total	FLU A (H1N1)	2009 (H1N1)	FLU A (H3N2)	FLU B	RSV A	RSV B	RSV Total	PARA 1	PARA 2	PARA 3	PARA 4	Corona 229E	Corona NL63	Corona OC43	Corona HKU1	Meta pneumo	Entero Rhino	ADENO	BOCA	Legio nella	Chla mydia	Myco plasma
JAN	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.7	0.3	0.0	0.0	0.0
FEB	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	6.1	0.2	0.3	0.0	0.0	0.0
MAR	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.4	0.1	0.1	0.3	0.1	1.4	0.9	0.1	0.4	12.2	1.2	0.3	0.0	0.1	0.1
APR	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.5	0.0	0.0	2.5	2.9	0.0	0.8	15.3	1.4	1.2	0.0	0.0	0.0
MAY	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.7	3.9	0.0	0.2	1.4	3.9	0.0	0.0	14.4	1.7	1.4	0.2	0.0	0.1
JUN	0.0	0.0	0.0	0.0	0.0	0.1	1.8	1.9	0.0	0.3	9.6	0.0	0.3	0.4	2.4	0.0	0.1	15.8	1.1	1.8	0.0	0.0	0.1
JUL	0.0	0.0	0.0	0.0	0.0	1.0	7.2	8.2	0.1	0.5	12.9	0.0	0.1	0.4	1.4	0.0	0.5	18.9	1.6	4.4	0.4	0.0	0.0
AUG	0.0	0.0	0.0	0.0	0.0	0.8	12.5	13.3	0.0	1.2	6.2	0.1	0.1	0.1	0.5	0.0	0.7	14.0	1.3	3.6	0.0	0.0	0.0
SEP	0.0	0.0	0.0	0.0	0.0	0.7	10.6	11.3	0.0	0.9	1.8	0.4	0.0	0.0	0.4	0.0	0.6	23.6	0.8	4.1	0.1	0.0	0.1
OCT	0.0	0.0	0.0	0.0	0.0	0.5	7.3	7.8	0.0	1.6	1.2	1.0	0.1	0.0	0.4	0.0	0.3	21.0	1.2	4.0	0.2	0.0	0.0
NOV	0.0	0.0	0.0	0.1	0.0	0.1	7.9	8.0	0.0	1.7	1.0	1.2	0.0	0.0	0.7	0.0	0.7	21.5	0.7	3.5	0.0	0.0	0.0
DEC																							

Increased prevalence of viruses: **Rhinovirus, RSV and Boca virus**



ACL RSV positivity rate - trends down

CDC Data RSV pos rate for Region 5 Chicago - (PCR – 15%↓, Antigen - 19% ↓)




CDC RSV positivity rate - trends down

SARS-COV-2					Influenza - no activity				RSV (Antigen+PCR)			
Week	IL % SCVPCR	WI % SCVPCR	IL % COVAG	WI % COVAG	IL % FLUPCR	WI % FLUPCR	IL % FLUAG	WI % FLUAG	IL % RSVAG	WI % RSVAG	IL % RSVPCR	WI % RSVPCR
Nov 14	4.7	9.0	7.5	21.7	0.5	0	n/a	0	18.2	23.2	15.0	25.0
Nov 7	3.8	7.4	6.6	17.6	0	0.3	n/a	0	18.4	25.0	21.4	27.7
Oct 31	3.8	6.3	4.8	13.7	0.3	0	n/a	0	18.6	25.0	20.9	32.2
Oct 24	3.7	5.6	5.1	16.7	0	0.2	n/a	0	19.0	29.3	22.5	30.6
Oct 17	3.7	6.5	7.0	18.0	0	0	0	0	20.0	36.0	27.0	31.3
Oct 10	4.3	7.6	5.0	18.2	0	0.2	0	0	22.2	31.8	23.9	32.6
Oct 3	5.0	8.6	6.0	16.6	0	0	0	0	20.0	34.0	24.9	35.5
Sep 26	5.0	8.1	4.4	15.2	0	0	0	0	27.7	35.9	30.0	37.7
Sep 18	4.9	9.0	7.2	17.5	0	0	0	0	33.0	31.0	28.0	39.6
Sep 12	6.5	9.6	5.9	20.5	0	0	0	0	20.0	21.9	41.6	43.7
Sep 5	6.2	8.3	7.0	22.4	0	0	0	0	33.3	43.9	38.1	40.5


ACL RSV tests results are consistent with RSV outbreak

ACL COVAG and SCVPCR - Pos rate (%) - Nov 14, 2021




ACL Covid positivity rate - trends up

Nov 3, 2021 - daily COVID-19 cases in US - CDC



CDC Covid positivity rate - trends up

Nov 13, 2021 – SARS-CoV-2 circulating in the US (~99.9% % Delta variants)



US vaccination status CDC | Data as of: Nov 4, 2021

426,728,092

Vaccines Administered

222,591,394

People who received at least one dose

193,227,813


People who are fully vaccinated*

67.0%

Percentage of the US population that has received at least one dose


58.2%

Percentage of the US population that has been fully vaccinated*




ACL Flu positivity rate – **limited activity** (2 pos out 1059 samples tested)

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, May 23, 2021 – November 6, 2021





CDC Midwest data as of: Nov 06, 2021 - (Flu 0.3 %)




2021-22 Influenza Season Week 44 ending Nov 06, 2021

ILI Activity Level




CSF targets positivity rate is 2.1%

ACL RMEPNL - CSF POSITIVE TARGETS - Nov 14, 2021



The most prevalent GI bacterial target is - (Crypto 1.5%)

ACL GPP - STOOL POS BACTERIAL TARGETS - Nov 15, 2021



The most prevalent GI viral target is – (Adeno – 0.2%)

